Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Switzerland
/
Pharmaceuticals & Biotech
Create a narrative
Roche Holding
SWX:ROG Community
Create a narrative
Roche Holding
Undervalued
Overvalued
Roche Holding
BA
bazza
Community Contributor
Roche Holding will see a 4.2576% revenue growth shaking the market
Valuation ### **Analyse der Roche Jahreszahlen 2024: Wachstum setzt sich fort, Herausforderungen bleiben_20250130 #### Zusammenfassung der Ergebnisse Roche hat für das Jahr 2024 ein solides Wachstum von 7 % auf 60,5 Mrd. CHF erzielt, was die Erwartungen leicht übertroffen hat.
View narrative
CHF 302.06
FV
3.8% undervalued
intrinsic discount
5.07%
Revenue growth p.a.
Set as Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
7 days ago
author updated this narrative
Roche Holding
WA
Analyst Price Target
Consensus Narrative from 19 Analysts
Advancing 7 New Therapies And Poseida Acquisition Will Expand Presence In Oncology By 2025
Key Takeaways Successful Pharma pipeline and innovative diagnostics launches are anticipated to drive long-term revenue growth and operating profit. Investments in strategic R&D and acquisition capabilities aim to enhance core profit and sustain competitive position in medicine development.
View narrative
CHF 305.60
FV
4.9% undervalued
intrinsic discount
3.91%
Revenue growth p.a.
Set as Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
8 days ago
author updated this narrative
Your Valuation for
ROG
Roche Holding
Your Fair Value
CHF
Current Price
CHF 290.60
2.4% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
75b
2015
2018
2021
2024
2025
2027
2030
Revenue CHF 75.4b
Earnings CHF 10.0b
Advanced
Set as Fair Value